A study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Trial Profile

A study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Milciclib (Primary)
  • Indications Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jun 2017 Results published in the Internet Document
    • 20 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top